The prevalence of sarcopenia is high in many organ pathologies such as COPD, but remains little studied in acute respiratory failure. Sarcopenia is a health problem representative of frailty, loss of autonomy and decreased muscle strength. The frequency and evolution of sarcopenia is unknown in patients having chronic bronchic obstruction with exacerbation.
* Investigator consecutively included patients with known persistent airflow obstruction, hospitalized in Pneumology Department at the CHU Gabriel Montpied in Clermont-Ferrand. * Investigator offered to participate to an observational study involving nutritional evaluation (recommended by national and international authorities) complementary to their usual respiratory care, and a 6 months' follow-up consultation: examination and surveys, mid-arm muscle circumference, body composition, spirometry. * This enables to assess sarcopenia as a low mid-arm muscle area, by measuring the mid-arm muscle circumference of the dominant side and the triceps skinfold thickness. * The primary endpoint is to determine the prevalence of sarcopenia, via the brachial muscular circumference, of chronic obstructive patients hospitalized in Pneumology department. * The data entry (clinical, biological and radiological) is carried out on site, during the initial consultation and follow-up, directly on the computerized patient file. These data will then be retrieved and entered in an Excel spreadsheet, anonymously (anonymous identification number, gender and age). * Management of censored data (lost to follow-up, cessation or withdrawal of study): each patient has a "computerized patient record" with phone numbers, checked during the first consultation and updated if necessary. The patient is called back one month before the follow-up consultation to confirm the appointment. If it is impossible to come, the patient will be offered another appointment, within one month of his initial appointment. * Lost participants will not be excluded from statistical analyses. * The expected number of subjects is 50. * Oral and written consent is asked at the beginning of the consultation proposing participation in the study and follow-up at 6 months.
Study Type
OBSERVATIONAL
Enrollment
54
Prevalence of sarcopenia in hospitalized chronic obstructive patients
CHU Clermont-Ferrand
Clermont-Ferrand, France
Prevalence of sarcopenia in hospitalized chronic obstructive patients
Time frame: at day 1
Evolution of sarcopenia after hospitalization
Time frame: at day 1
Determination of the factors influencing this evolution
Time frame: at day 1
Determination of phenotypes from anthropometric, functional and nutritional biological parameters
Time frame: at day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.